Literature DB >> 2591400

HLA-haploidentical bone marrow transplantation in three infants with adenosine deaminase deficiency: stable immunological reconstitution and reversal of skeletal abnormalities.

R Bluetters-Sawatzki1, W Friedrich, W Ebell, U Vetter, H Stoess, S F Goldmann, E Kleihauer.   

Abstract

Three infants with severe combined immunodeficiency and adenosine deaminase (ADA) deficiency were treated by T-cell depleted bone marrow transplantation (BMT), using human leukocyte antigen (HLA)-haploidentical parents as donors. In the first patient, two initial transplants failed to engraft and no change of the immunodeficiency was observed. In order to overcome this graft resistance, cytoreductive conditioning was used prior to a third transplant. In the other two patients, similar conditioning was used prior to initial transplants. In all three patients, complete and permanent immunological reconstitution was observed and they survive from 3.5 to 5 years after transplantation. In biopsies obtained from iliac bones prior to BMT, osteochondral abnormalities characteristic of ADA-deficiency were noted in all three patients. After successful transplantation, these abnormalities had completely resolved. Our results demonstrate that cytoreductive conditioning prior to HLA-haploidentical BMT is useful in order to obtain stable engraftment and reversal of abnormalities associated with ADA deficiency.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2591400     DOI: 10.1007/bf01995857

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  19 in total

1.  Lymphoma in a patient with severe combined immunodeficiency with adenosine deaminase deficiency, following unsustained engraftment of histoincompatible T cell-depleted bone marrow.

Authors:  N Kapoor; L K Jung; D Engelhard; J Filler; I Shalit; K S Landreth; R A Good
Journal:  J Pediatr       Date:  1986-03       Impact factor: 4.406

2.  Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation.

Authors:  R H Buckley; S E Schiff; H A Sampson; R I Schiff; M L Markert; A P Knutsen; M S Hershfield; A T Huang; G H Mickey; F E Ward
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

3.  The chondro-osseous dysplasia of adenosine deaminase deficiency with severe combined immunodeficiency.

Authors:  S D Cederbaum; I Kaitila; D L Rimoin; E R Stiehm
Journal:  J Pediatr       Date:  1976-11       Impact factor: 4.406

4.  Adenosine deaminase deficiency: disappearance of adenine deoxynucleotides from a patient's erythrocytes after successful marrow transplantation.

Authors:  S H Chen; H D Ochs; C R Scott; E R Giblett; A J Tingle
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

5.  Immunoreconstitution in severe combined immunodeficiency after transplantation of HLA-haploidentical, T-cell-depleted bone marrow.

Authors:  W Friedrich; S F Goldmann; U Vetter; T M Fliedner; B Heymer; H H Peter; Y Reisner; E Kleihauer
Journal:  Lancet       Date:  1984-04-07       Impact factor: 79.321

6.  Reconstitution of T- and B-cell function after T-lymphocyte-depleted haploidentical bone marrow transplantation in severe combined immunodeficiency due to adenosine deaminase deficiency.

Authors:  G M Silber; J A Winkelstein; R C Moen; S D Horowitz; M Trigg; R Hong
Journal:  Clin Immunol Immunopathol       Date:  1987-09

7.  Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency.

Authors:  S H Polmar; R C Stern; A L Schwartz; E M Wetzler; P A Chase; R Hirschhorn
Journal:  N Engl J Med       Date:  1976-12-09       Impact factor: 91.245

8.  Successful haploidentical mismatched bone marrow transplantation in severe combined immunodeficiency: T cell removal using CAMPATH-I monoclonal antibody and E-rosetting.

Authors:  G Morgan; D C Linch; L T Knott; E G Davies; C Sieff; J M Chessells; G Hale; H Waldmann; R J Levinsky
Journal:  Br J Haematol       Date:  1986-03       Impact factor: 6.998

9.  Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase.

Authors:  M S Hershfield; R H Buckley; M L Greenberg; A L Melton; R Schiff; C Hatem; J Kurtzberg; M L Markert; R H Kobayashi; A L Kobayashi
Journal:  N Engl J Med       Date:  1987-03-05       Impact factor: 91.245

10.  Bone-marrow transplantation for immunodeficiencies and osteopetrosis: European survey, 1968-1985.

Authors:  A Fischer; C Griscelli; W Friedrich; B Kubanek; R Levinsky; G Morgan; J Vossen; G Wagemaker; P Landais
Journal:  Lancet       Date:  1986-11-08       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.